UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2014

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

33-0827593

001-34375

Delaware

(State or other jurisdiction of incorporation) (Commission File Number)		•	(I.R.S. Employer Identification No.)					
3020 Callan Road, San Diego, California 92121 (Address of principal executive offices) (Zip Code)								
	(Regi	(858) 458-0900 istrant's telephone number, including are	ea code)					
	n/a (Former name or former address, if changed since last report)							
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):								
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)							
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)							
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))							
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))							

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July 15, 2014, Mr. Ruud J.P. Jona notified Cytori Therapeutics, Inc., a Delaware corporation (the "Company"), of his decision to resign from the Company's Board of Directors, such resignation to be effective immediately. Mr. Jona's decision to resign as a director did not involve any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTORI THERAPEUTICS, INC.

Date: July 21, 2014 By: /s/ Mark E. Saad

Mark E. Saad Chief Financial Officer